- Todos Medical (OTCQB:TOMDF +7.0%) selected the brand name "Tollovid" for its proprietary, patent protected 3CL protease inhibitor, previously called NLC-001.
- In September 2020, Todos licensed the exclusive worldwide distribution rights for Tollovid, excluding Israel, from Israel-based joint venture partner NLC Pharma.
- Tollovid is an orally administered proprietary blend of plant extracts that includes a powerful 3CL protease inhibitor that helps support and maintain healthy immune function.
- 3CL protease plays a vital role in the intracellular replication of coronaviruses and 3CL protease inhibition is being evaluated as a potential therapeutic target for COVID-19 by several groups, including Pfizer.
- Also, the company entered into a private label and distribution agreement with NY City-based The Alchemist's Kitchen, leading botanical wellness destination.